<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071262</url>
  </required_header>
  <id_info>
    <org_study_id>17229</org_study_id>
    <secondary_id>I3Y-JE-JPCQ</secondary_id>
    <nct_id>NCT04071262</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Study of Abemaciclib in Combination With Other Anti-Cancer Therapy in Japanese Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the study drug abemaciclib in combination with other
      anti-cancer therapies is safe in Japanese participants with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">July 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Number of Participants with DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Abemaciclib in Combination with Abiraterone Acetate plus Prednisolone</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of Abemaciclib in Combination with Abiraterone Acetate plus Prednisolone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Abemaciclib in Combination with Abiraterone Acetate plus Prednisolone</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Cmax of Abemaciclib in Combination with Abiraterone Acetate plus Prednisolone</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Abemaciclib + Abiraterone Acetate + Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib, abiraterone acetate and prednisolone given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Abiraterone Acetate + Prednisolone</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Abiraterone Acetate + Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Abiraterone Acetate + Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant with histologically confirmed adenocarcinoma of the prostate.

          -  Participant with metastatic disease documented by positive bone scan and/or measurable
             soft tissue metastatic lesions by computed tomography (CT) or magnetic resonance
             imagining (MRI).

          -  Participant who has serum testosterone level is â‰¤1.73 nanomoles per liter (nmol/L) (50
             nanograms per deciliter).

          -  Participant who has progressive disease at study entry demonstrated during continuous
             androgen-deprivation therapy (ADT)/post orchiectomy.

          -  Participant with adequate organ function.

          -  Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

        Exclusion Criteria:

          -  Participant who was treated with cytochrome P450 (CYP)17 inhibitors (including
             abiraterone acetate, TAK-700, TOK-001, and ketoconazole).

          -  Participant who was treated with abemaciclib or any cyclin dependent kinase 4 and 6
             (CDK4 and 6) inhibitors.

          -  Participant who has prior cytotoxic chemotherapy for metastatic castration-resistant
             prostate cancer (mCRPC), prior radiopharmaceuticals for prostate cancer (PCa), or
             prior sipuleucel-T.

          -  Participant who has gastrointestinal disorder affecting absorption or inability to
             swallow large pills.

          -  Participant who has clinically active or chronic liver disease, moderate/severe
             hepatic impairment, ascites, or bleeding disorders secondary to hepatic dysfunction.

          -  Participant who has known or suspected central nervous system metastatic disease.

          -  Participant who was treated with drugs known to be strong inhibitors, or strong or
             moderate inducers of cytochrome P450 3A4 (CYP3A4) and the treatment cannot be
             discontinued or switched prior to starting study treatment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

